

Osteoporosis: An Under-appreciated Complication of Diabetes

Sue A. Brown, MD, and Julie L. Sharpless, MD

The extension of the average life expectancy of people with diabetes that has accompanied improvements in medical care has increased the significance of osteoporosis. In addition to the usual causes of osteoporosis associated with aging, bone health is also compromised by diabetes. There is strong evidence that patients with type 1 diabetes and increasing evidence that those with type 2 diabetes have an increased risk of certain types of osteoporotic fractures. Several mechanisms have been proposed for diabetes-related osteoporosis. These include both the comorbidities of diabetes and more direct pathophysiological effects of the disease itself.

Osteoporosis and its resultant fractures are increasing as the population ages, making assessment of skeletal health an important component of routine care. Osteoporosis is a disorder of increased bone fragility and low bone mass with a consequent increase in fracture risk.¹ Data from the third National Health and Nutrition Examination Survey (NHANES III) indicate that 13–18% of women in the United States over age 50 have osteoporosis and an additional 37–50% have low bone mass at the hip.² The disease results in more than 350,000 hip fractures alone each year in the United States, and the annual number of fractures is expected to double by 2025.^{3,4}

Fortunately, recent advances have been made with therapies that significantly decrease fracture risk. But despite these extraordinary advances, it is alarming that more than 80% of patients with a recent hip or wrist fracture are not getting anti-osteoporosis therapy.^{5,6} In this

article, we review the presentation of osteoporosis in diabetes, potential mechanisms, prevention, and treatment.

Fractures

Hip fractures in particular are now recognized not only as a major cause of morbidity and mortality, but also for their significant economic and social impact. At age 50, a white woman in the United States has a 17% chance of sustaining a hip fracture³ and a 32% chance of sustaining a vertebral fracture in her lifetime.⁷ Hip fractures cause the most morbidity, with reported mortality rates up to 20–24% in the first year after a hip fracture.^{8,9} Although some excess mortality may be attributable to comorbid factors rather than the hip fracture itself, up to 50% of patients are unable to walk without assistance, and 33% are totally dependent or in a nursing home in the year following a hip fracture.^{8,10,11}

IN BRIEF

Care of patients with diabetes should include an assessment of bone health. It is now clear that patients with type 1 diabetes have lower bone mineral density (BMD) and higher risk of fractures. Evidence is accumulating that patients with type 2 diabetes who have complications are also at increased risk of certain types of osteoporotic fractures despite having a higher BMD when compared to patients with type 1 diabetes. Therapeutic interventions are key to preventing fractures, both by improving bone density and decreasing the risk for falls.

Vertebral fractures are also associated with significant comorbidity from pain, chronic disability, and reduced quality of life.¹²

Hip fractures are increased in patients with diabetes. Case-control studies of patients with hip fractures have found an excess of patients with diabetes, suggesting at least a twofold relative risk in all patients with diabetes.¹³ Women with type 1 diabetes had a 6.9- to 12-fold relative risk of hip fractures compared to women without diabetes.^{14,15}

Data are less clear about the risk of hip and vertebral fractures in patients with type 2 diabetes. Most studies in women with type 2 diabetes have also found an increased risk of hip fractures,^{13–16} with estimates of relative risk almost double the risk in other postmenopausal women. The Study of Osteoporotic Fractures in women older than 65 years with type 2 diabetes found an increased risk of hip and proximal humerus fractures despite a higher bone mineral density (BMD) in those patients.¹⁷ There was also a trend toward increased risk of vertebral, forearm, ankle, and foot fractures. In contrast, other investigators have found increased BMD at the spine in men and women with type 2 diabetes, with fewer fractures.^{18,19}

The one site with an undisputed increased fracture risk is the foot, which may be related in part to obesity or neuropathy.^{17,20,21} Focal osteopenia and fractures associated with severe peripheral neuropathy (Charcot foot) are long recognized as a complication of any type of diabetes. Mortality is high in the general

population with hip fractures, but the presence of diabetes in a patient with a hip fracture is a risk factor for increased mortality.²²

Bone Density

Although many factors, including number and type of falls, influence the probability of fractures, the most significant factor is the strength of the bone itself. In the absence of clinically available methods to assess bone quality directly, we rely on the measurement of BMD. A strong relationship exists between bone density measurements and fracture risk: a 10% decrease in BMD at any site confers a 1.6–2.6 increased relative risk of hip fracture and a 1.7–2.3 increased relative risk of vertebral fracture.²³

Recent advances in bone densitometry techniques have allowed more precise and accurate measurement of BMD at multiple sites. Early studies used single-photon and dual-photon absorptiometry. BMD is now typically performed using dual-energy x-ray absorptiometry (DXA) at the spine, hip, and wrist. More recent data are therefore more sensitive to differences between groups, facilitating the recognition of differences in patients with diabetes.

Even newer ultrasound techniques are appealing because of their lower cost and lack of radiation exposure as well as the theoretical benefits of evaluating an aspect of bone quality. Ultrasound has been correlated with fracture risk but is not standardized, and results vary across machines.²⁴ Portable DXA machines are able to assess peripheral sites (calcaneus and radius), but generalized fracture risk prediction is not well studied. However, both ultrasound and peripheral DXA still need to be validated in patients with diabetes because local changes in the bones of the foot resulting from peripheral neuropathy may affect results.²⁵ Quantitative CT and MRI are primarily research tools used to assess different types of bone: trabecular (vertebral bodies) versus cortical (radial shaft).

Using DXA, BMD is categorized by a T score in reference to young normal BMD. The World Health Organization (WHO) has established T score criteria to estimate fracture risk, with a T score of 1–2.5 standard deviations below normal representing osteopenia and > 2.5 standard deviations below normal representing osteoporosis.²⁶

Osteopenia was initially described in adolescents with diabetes, 50% of whom were found to have decreased cortical and trabecular forearm BMD.²⁷ Several subsequent studies found that the forearm BMD in children with only 4–6 years of type 1 diabetes was 20–50% lower than that in control sub-

jects.²⁸ One study examining vertebral BMD found a decreased cortical but not trabecular BMD in children with diabetes.²⁹ Most studies in children and adults confirm that BMD is lower in patients with type 1 diabetes than in subjects without diabetes.^{30–33}

In contrast, studies in women with type 2 diabetes, controlling for age and obesity, show BMD that is either the same or greater than that in normal subjects,^{18,19} even in patients treated with insulin³¹ (Figure 1). The Rancho Bernardo studies, a large population-based longitudinal cohort, also looked at men with type 2 diabetes and found that their BMD was similar to that of men with




Figure 1. Mean age and BMI adjusted BMD at the proximal femur in subjects with type 1 diabetes (29 men, 27 women), type 2 diabetes (34 men, 34 women), and without diabetes (240 men, 258 women). Reprinted with permission from ref. 31.

normal glucose tolerance, despite the increased BMD they found in women with diabetes.³⁴

Mechanisms

Is osteoporosis another complication of poor glycemic control? No correlation between BMD and diabetes duration or current glycemic control (by hemoglobin A1c [A1C]) was seen in postmenopausal women (8.9 years duration, 14 years postmenopausal),³⁵ or children (5.2 years duration, excluded if complications).²⁹ Short-term measures of control, such as glucose levels or A1C results, would not be expected to reflect cumulative bone damage measured by BMD. This was demonstrated by Valerio et al.³² in children with 6.9 years of diabetes in whom the latest A1C did not correlate with lumbar BMD, but the A1C averaged over the entire duration of diabetes did correlate with BMD.

Diabetes complications also represent cumulative results of long-term poor control. Several investigators have demonstrated an association between BMD and microvascular complications, with the BMD inversely correlated with the presence and extent of microvascular complications in women with normal menstrual cycles.^{30,36} Mathiassen et al.³⁷ followed the BMD of 19 patients with type 1 diabetes (8 women), initially free of complications, and found that after 11 years, only those who developed retinopathy or proteinuria had worsening of their BMD. The presence of severe peripheral neuropathy in patients with type 1 diabetes has also been found to correlate with decreased BMD at all sites, in comparison to patients with type 1 diabetes without neuropathy and in comparison to healthy subjects.²⁵ Although these were small groups, they were matched for other complications and for activity levels.

Using the same paradigm, Forst et al.³⁸ found a decreased BMD in the cortical bone at the hip and a greater decrease at the distal limb in association with peripheral neuropathy. The lumbar spine had a nonsignificant decrease in BMD in

these patients with type 1 diabetes. In the Blue Mountain Eye Study in Australia,³⁹ an association between retinopathy and all fractures was seen in both men and women with all types of diabetes.

Some studies have shown stabilized and improved BMD in patients with type 1 diabetes with improved glucose control over time.^{40,41} Hypercalciuria, a potential risk factor for osteoporosis, has long been noted in patients with poorly controlled type 1 diabetes^{42,43} or type 2 diabetes,^{44,45} and was shown to improve with lower A1C results.⁴⁶ Thus, metabolic control appears to be a major factor in the increased incidence of osteoporosis in patients with diabetes. However, poor control cannot be the only factor unless there is a compensatory factor increasing BMD in type 2 diabetes.

If the relationship between osteoporosis and diabetes were only related to hyperglycemia, one would expect a similar incidence of osteoporosis in patients with type 1 and those with type 2 diabetes, but most studies show more osteoporosis in patients with type 1 diabetes.^{31,47} There may be differences between types of diabetes other than glucose control that affect BMD. Several factors have been investigated, including treatment with insulin, endogenous insulin levels, age of onset, and A1C, but the actual mechanism for lower BMD in type 1 diabetes is not known.

Krakauer et al.⁴⁰ and Tuominen et al.³¹ have separately compared patients with type 1 and type 2 diabetes treated with insulin, showing that exogenous insulin is not the cause of the bone loss. Krakauer et al. also found decreased BMD in men and women with type 1 diabetes as compared with those with type 2 diabetes or with control subjects.

Epidemiological studies at Rancho Bernardo, Calif.,⁴⁸ and in Rotterdam, The Netherlands,⁴⁹ suggested correlations between fasting and post-challenge insulin levels and BMD in women without diabetes, but in the Rotterdam group only, these lost significance after adjusting for BMI. In patients with type 2 diabetes, no consistent association of BMD

with endogenous insulin levels, using fasting or post-challenge levels, has been found.^{34,50,51} However, insulin levels are quite variable within type 2 diabetes because of the decline of β -cell function over the course of the disease.

An autoimmune- or inflammation-mediated process has also been considered because a decrease in BMD has been noted during the first several months to years after diagnosis, with an attenuation thereafter.^{27,37,52} This suggests an initial insult not specifically related to control, but perhaps to the autoimmune process, similar to that seen in rheumatoid arthritis, in which bone loss is seen in the involved joints.

Increasing evidence suggests that type 1 diabetes in particular may impede new bone formation possibly because of defective function of osteoblasts, the primary cells responsible for bone formation.^{53,54} Preliminary data suggest that poorly controlled diabetes with hyperglycemia and consequently increased osmolarity contribute to decreased osteoblast function.⁵³ In addition, patients with type 1 diabetes are known to have lower levels of insulin-like growth factor I, an anabolic hormone that maintains healthy bone formation.⁵⁵

Markers of Bone Turnover

Serum and urine markers of bone turnover have been developed to assess short-term changes leading to osteoporosis. Serum levels of alkaline phosphatase and osteocalcin reflect bone formation, whereas serum levels of collagen cross-links reflect bone resorption. Osteoblast secretion of osteocalcin is decreased by high glucose levels, so bone formation as assessed by osteocalcin is decreased in proportion to diabetes control.⁵⁶ Thus, the markers are applicable only in limited situations and often require very good glycemic control and stability to be useful.

Bone resorption measured by deoxypyridinoline after a 12-hour glucose clamp was greater in age- and height-for-age-matched adolescents with diabetes than in control subjects, sug-

gesting that bone loss in early-onset type 1 diabetes is related to increased turnover.⁵⁷ This is important because instead of the presumed high turnover rate, as can occur with excess cortisol or with hyperparathyroidism, a low turnover resulting in adynamic bone, also seen in renal failure, is an alternate mechanism for osteoporosis. This possibility is also supported by the observation that fractures take a longer time to heal in diabetes.⁵⁸ Krakauer et al.⁵⁹ have proposed the possibility of a low turnover state due to functional hypoparathyroidism and hyperglycemia to account for the differences between type 1 and type 2 diabetes, but this has yet to be investigated. The heterogeneity of types of diabetes, as well as variable contributions from associated conditions affecting BMD, make it difficult to designate one underlying mechanism for diabetic osteopenia.

Risk Factors for Low Bone Mass or Fractures

Multiple risk factors have been identified that may contribute to low bone mass. Risk factors consistently associated with osteoporosis include female sex, Caucasian, low body weight (< 127 lb), and maternal or personal history of fractures.^{60,61} Risks factors particular to patients with diabetes are included in Table 1.

Fractures are the most specific risk factor. A history of any previous fracture increases the risk of further fracture by at least twofold.⁶² Patients with a vertebral fracture will be three to five times more likely to suffer another vertebral fracture within the next year^{62,63} and are also at increased risk of sustaining a hip fracture when compared with women without a vertebral fracture.⁶⁴

A hip fracture occurs most typically after sustaining a fall.⁶⁵ In the Study of Osteoporotic Fractures, older women with diabetes were found to have an increased risk of falls, which was increased even further in insulin users.⁶⁶

Bone density decreases with age, as fracture risk rises rapidly.¹⁰ Fracture risk

varies by race, with hip fracture rates in African-American women reported to be one-third that of white women.^{7,67} African-American and possibly Hispanic women tend to have higher BMD values when compared with white women, although these effects are less apparent when BMD is corrected for bone size.^{68,69}

Diabetes-Associated Risk Factors

As discussed above, poor metabolic control is a risk for osteoporosis and fractures in diabetes. Additionally, factors extrinsic to the metabolic changes of diabetes, such as age of onset of type 1 diabetes in relation to stage of bone growth, or lifestyle factors such as obesity and inactivity in type 2 diabetes, have secondary consequences relative to BMD.

One such age-related risk for osteoporosis is low peak BMD. In American women, peak BMD is achieved by the

end of the third decade.⁶⁸ Thus, to the extent that diabetes may cause osteopenia, women who are young at diabetes onset may never achieve a normal peak bone density and thus reach osteoporotic thresholds earlier in life (Figure 2).

Delayed puberty is associated with a lower peak BMD;⁷⁰ therefore girls with diabetes and delayed menarche may also reach a lower peak BMD. One carefully controlled Finnish study by Tuominen et al.³¹ defined type 1 diabetes by C-peptide values and therefore was able to use only subjects who had been diagnosed after age 30. Even in these patients, BMD was lower in patients with type 1 diabetes compared with those with type 2 diabetes or with control subjects, suggesting a secondary loss of bone.

Another age-related factor is estrogen status, the major cause of osteoporosis in the general population. Because of their increased risk for menstrual dysfunction,⁷¹ women with type 1 diabetes may also have osteopenia due to estrogen deficiency. Most studies have not assessed the menstrual histories in these women, but one study did find a positive correlation between oral contraceptive use and BMD in women with type 1 diabetes, supporting a component of estrogen deficiency.⁷²

Eating disorders, which are more common in patients with diabetes, are associated with decreased bone density.⁷³ One of the strongest predictors of osteoporosis is low body weight,⁷⁴ which is more typical of patients with type 1 diabetes than of those with type 2 diabetes. The obesity commonly present in people with type 2 diabetes (and often for years before it develops) may have a cumulative protective effect on bone density.

Among women with osteoporosis, almost all hip fractures result from falls.⁷⁵ The risk of falling is increased by diabetic complications including impaired vision from retinopathy or cataracts and poor balance and orthostatic hypotension from peripheral and autonomic neuropathy. Acute hypo- and hyperglycemia may also cause impaired vision, poor coordination, and muscle

Table 1. Risk Factors for Osteoporotic Fractures in Diabetes

Risks for Osteoporosis

Directly due to diabetes

- Type 1 diabetes
- Poor glycemic control
- Nephropathy

Due to complications of diabetes

- Neuropathy
- Diabetic diarrhea

Due to diseases associated with diabetes

- Grave's disease
- Celiac sprue
- Amenorrhea
- Delayed puberty
- Eating disorders

Risks for Falls

- Episodes of hypoglycemia
- Episodes of nocturia
- Poor vision due to retinopathy or cataracts
- Poor balance due to neuropathy, foot ulcers, or amputations
- Orthostatic hypotension
- Impaired joint motility due to cheiropathy




Figure 2. Model for the effects of diabetes on BMD at different times of life. Initial adolescent accumulation of bone is diminished (1), thus reaching a lower plateau with continued loss associated with hypercalciuria in early adult life (2), followed by later onset and retardation of age-related bone loss (3). Depending on the age of onset, stages could overlap. Reprinted with permission from ref. 40.

weakness. Patients with extensive neuropathy, foot ulcers, or amputations are at increased risk for falls and immobility-induced osteoporosis because of their limited mobility⁷⁶ (Table 1).

Several other diseases that increase the risk of osteoporosis are particularly relevant in diabetes. Diseases associated with autoimmune diabetes, including Graves' disease and celiac sprue, also carry an independent risk for osteoporosis. Treatments for hypertension and hyperlipidemia, which are associated with both types of diabetes, may also affect BMD. Use of loop diuretics to treat hypertension can increase urinary loss of calcium, whereas thiazides may decrease it. Interestingly, the large Canadian Multicentre Osteoporosis Study found an increase in BMD measurements in men and women with hypertension, even after adjusting for expected confounding factors such as type 2 diabetes, BMI, and thiazide use.⁷⁷ Although case-control studies have suggested that treatment of hyperlipidemia with HMG CoA reductase inhibitors may increase BMD,⁷⁸ these results have not been supported by other studies.⁷⁹

There are preliminary data in animal studies that suggest thiazolidinediones, via actions on PPAR γ , may interfere with bone regulation.^{80,81} The PPAR $\gamma 2$ isoform may be important for differentiation of osteoblasts and adipocytes from a common progenitor cell. One group has reported that activation of PPAR γ may inhibit differentiation of osteoblasts or bone-forming cells. These results remain to be proved in human studies, and differences among thiazolidinediones may need to be investigated.

Screening Recommendations

There are no osteoporosis screening recommendations specifically for patients with diabetes. The U.S. Preventative Task Force recommends that screening should be routinely provided in all women over age 65 and in those women ages 60–64 who are at increased risk.⁸² Risk factors were noted to be difficult to identify, but low body weight (< 70 kg) was found to be the best single predictor of low bone density. The National Osteoporosis Foundation also recommends screening for younger postmenopausal women (younger than age

65) who have had a fracture or who have one or more risk factors for osteoporosis. In patients with diabetes who do not yet meet these criteria, there are not yet evidence-based recommendations, but common sense would suggest BMD screening for type 1 patients, female or male with any complications, and thin women with other extensive complications of diabetes.

The age of the patient must be a factor since fracture risk is a function of age. Identification of osteopenia in a younger individual may help adherence with lifestyle interventions (adequate calcium, vitamin D, exercise, maintenance of regular menstrual cycles). It should be emphasized, however, that maintenance of healthy bone remodeling rather than near-term fracture prevention is the focus at younger ages since the 10-year fracture risk is low (< 10% at age 45 with osteoporosis by BMD).⁸³ Therefore, other therapeutic interventions (e.g., bisphosphonates) are rarely indicated.

Measures to Prevent Osteoporosis

In all individuals at risk for osteoporosis, appropriate nutrition and lifestyle interventions should be considered. Calcium is an accepted adjunct to anti-osteoporosis therapy. The National Academy of Science and National Institutes of Health recommend calcium intakes of 1,000–1,500 mg/day and vitamin D of at least 400–800 IU for postmenopausal women, particularly in individuals with little sun exposure.^{84,85} A meta-analysis of all forms of vitamin D therapy suggest that overall there may be a reduced incidence of vertebral fractures.⁸⁶

Regular exercise is important for healthy bone remodeling and to maintain muscle coordination and balance to decrease falls and therefore should be emphasized as an additional consideration beyond its benefits on glycemic control, atherosclerotic risk, and weight control.⁸⁷ Likewise, osteoporosis is one more reason smoking cessation is important for all patients with diabetes, although the effect of smoking on

osteoporosis outcomes is not rigorously studied.

Preventing falls in patients with diabetes is paramount, and beneficial interventions include muscle strengthening and balance retraining (use of walkers), home hazard assessment (use of night-lights), withdrawal of psychotropic medications, and use of multidisciplinary risk factor assessment programs.⁸⁸ Hip protectors have been demonstrated to reduce the risk of fractures in frail elderly adults.⁸⁹ These issues should be addressed in all diabetes patients with severe retinopathy or neuropathy or other risk factors discussed above.

Treatment Options

Any individual with a fracture should receive additional therapy, preferably with a bisphosphonate that has proven efficacy for hip and vertebral fracture reduction. It should be noted that the current treatment regimens have not been specifically tested in patients with diabetes and osteoporosis. Pamidronate (a bisphosphonate), however, has been efficacious in small studies of Charcot neuroarthropathy.⁹⁰

The use of estrogen or estrogen-progesterone therapy continues to be a complex decision often based on factors other than osteoporosis benefits. In postmenopausal women who have not yet had a fracture but who have low BMD and risk factors, raloxifene or a bisphosphonate may be indicated, but this estrogen-antagonist should not be used in premenopausal women. Calcitonin should be relegated to second-line therapy but may be used in individuals who are unable to tolerate other regimens.

Parathyroid hormone (PTH) should be reserved for those at greatest risk (continuing fractures) initially due to its cost. The role of PTH in osteoporosis management, particularly in combination with bisphosphonates or for first-line management of fracture, is expected to be further clarified.

When considering therapeutic effects of osteoporosis agents, it should be rec-

ognized that most agents are primarily studied in Caucasian women who have adequate calcium and vitamin D intakes. For additional details, readers are referred to recent reviews of osteoporosis therapies^{91,92} and to the summary of selected therapies in Table 2.

Clinical Considerations for Therapeutic Interventions

Treatment of osteoporosis for patients with diabetes is similar to that for patients without diabetes, except for those with nephropathy or gastrointestinal complications. Renal impairment necessitates evaluation of the parathyroid-vitamin D axis as well as dose adjustment of medications. Defects in bone metabolism in advanced renal disease are complex and require adequate therapies directed at bone turnover, phosphate control, and vitamin D suppression of PTH and have been recently reviewed in detail.⁹³ The current therapies for osteoporosis have not been clinically studied in renal failure. Gastroparesis, malabsorption or sprue, and diabetic diarrhea can all contribute to osteoporosis by interfering with calcium and vitamin D absorption and require separate evaluation and treatment.

Hormone therapy

Estrogen therapy has a consistent positive effect across trials in respect to increasing BMD (by 4–7% after 2 years) both in younger perimenopausal women and older postmenopausal women.^{94,95} The Women's Health Initiative (WHI) is a large, randomized placebo-controlled trial of estrogen/progesterone therapy designed to demonstrate fracture efficacy.⁹⁶ Fractures of any type, including hip and vertebral fractures, were reduced with estrogen/progesterone therapy, resulting in five fewer hip fractures per 10,000 person-years of use.

These results are particularly important since hip fractures cause the most morbidity, and only one other class of agents, the bisphosphonates, has con-

vincingly resulted in hip fracture reduction. Given the complexity of decision-making regarding estrogen therapy and the WHI conclusion that overall fracture benefit did not outweigh an increased global index of risk, the individual decision remains as always between patients and their providers.

Bisphosphonates

Bisphosphonates are potent inhibitors of bone resorption that increase BMD and reduce vertebral and non-vertebral fractures. Their oral bioavailability is low, and absorption is easily impaired (e.g., by calcium); thus they should be taken on an empty stomach. Additional recommendations include remaining upright and drinking water to ensure that tablets do not remain or reflux into the esophagus due to reports of esophagitis.⁹⁷

Bisphosphonates have a long half-life in bone, with a continued decrease in bone loss for several years after cessation. Alendronate and risedronate have proven efficacy in the prevention and treatment of osteoporosis.^{98,99} Both alendronate and risedronate are available in once-weekly doses that have been less well studied for fracture outcomes but increase BMD by a similar degree to daily dosing and may have better acceptability to patients.¹⁰⁰ No differences in gastrointestinal tract tolerability have been found for the different dosing regimens of alendronate.¹⁰¹

Selective estrogen receptor modulators

The WHI report has resulted in increased interest in alternatives to hormone therapy, particularly in selective estrogen receptor modulators such as raloxifene. Raloxifene acts as an agonist on bone and cholesterol metabolism and an antagonist at breast tissue and appears to have a neutral effect on uterine tissues.¹⁰² Raloxifene does have the same clotting risks as estrogen and has not yet been studied with regard to the cardiovascular endpoints that terminated the WHI.

Table 2. Selected Therapeutic Agents for the Treatment of Osteoporosis

Class	Drug	Typical dose	Potential adverse effects	Increase in spine BMD (duration of therapy) ^{106,110,124}	Vertebral fracture reduction?	Hip fracture reduction?
Hormone therapy	Estrogen + progesterone	0.625 mg/2.5 mg by mouth daily	Venous thromboembolism; breast cancer	5–7% (2 years)	+++	++
Bisphosphonates	Alendronate	10 mg by mouth daily or 70 mg by mouth once a week	Administer while fasting, with 8 oz. water in upright position for 30 min. to prevent pill-induced esophagitis; contraindicated if CrCl < 30–35 cc/min;	5–6% (2–3 years)	+++	++
	Risedronate	5 mg by mouth daily or 35 mg by mouth once a week	abdominal pain, dyspepsia	4–5% (1.5–3 years)	+++	++
Selective estrogen receptor modulator	Raloxifene	6 mg daily	Venous thromboembolism; hot flashes	2–3% (2–3 years)	+++	No*
Calcium regulating hormone	Calcitonin	200 IU nasal spray daily	Rhinitis	1–3% (5 years)	+	No
Anabolic hormone	Parathyroid hormone (teriparatide or rhPTH 1–34)	20 µg subcutaneously	Arthralgias; transient orthostatic hypotension; contraindicated with nephrolithiasis or bone metastases	9% (18 months)	+++	Non-vertebral combined (++)**

+++ = strong consistent effects; ++ = consistent effects; + = some effects; rhPTH = recombinant human parathyroid hormone; CrCl = creatinine clearance
 *Not yet demonstrated for hip fracture reduction. The MORE trial¹⁰³ enrolled slightly younger women than the bisphosphonate trials demonstrating hip fracture reduction.^{125,126}
 **Has demonstrated efficacy in reducing nonvertebral fractures combined but not hip fractures alone.

The largest placebo-controlled randomized controlled trial to evaluate the effects of raloxifene on fracture outcomes was the Multiple Outcome of Raloxifene Evaluation (MORE) trial of 7,705 postmenopausal women.¹⁰³ Despite only modest increases in BMD (2–3% in 3 years), a significant decrease in vertebral fractures was found in both patients with osteoporosis by BMD and those with vertebral fractures. The MORE data showed that despite relatively modest BMD increases compared to the bisphosphonates, similar absolute reductions in vertebral fractures can be found. However, no reduction in nonvertebral fractures (particularly hip) has been shown.

With respect to patients with diabetes in the MORE trial, raloxifene was not found to impair glycemic control and had similar favorable effects on lipid profiles as in women without diabetes.¹⁰⁴ In addition, abstracts from the MORE trial have reported no difference in BMD improvement or bone turnover markers in patients with or without diabetes.¹⁰⁵

Calcitonin

Calcitonin, an endogenous peptide that inhibits bone resorption, is available in nasal and subcutaneous forms that make it an appealing alternative for women who do not tolerate bisphosphonates or raloxifene. However, it should be rele-

gated to second-line therapy due to the lack of convincing fracture efficacy. Although a meta-analysis found calcitonin decreased vertebral fractures, most subjects were in the PROOF trial, which has come under scrutiny because of its lack of dose-response effect and significant loss to follow-up, which limits conclusions regarding its effect on vertebral fracture.¹⁰⁶

PTH

PTH (1–34 fragment) is a new anabolic agent directed at stimulating bone formation. Increases in BMD at the spine are greater than those achieved with the anti-resorptive regimens discussed previously

with rates up to 7–13% at the spine with no change or increases of 3% reported at the femoral neck.^{107–109} The largest randomized controlled trial found reduced vertebral and nonvertebral fragility fractures after a median of 21 months of therapy in 1,637 postmenopausal women with vertebral fractures.¹¹⁰ Adverse events may include mild asymptomatic hypercalcemia occurring early in treatment.¹¹⁰ Preclinical studies in rats given long-term PTH at high doses found an increased risk of osteosarcoma.¹¹¹ This has not been observed in any human studies but had led the Food and Drug Administration to limit therapy duration to 2 years.

Combination therapies

Estrogen has been studied in combination therapy with alendronate,^{112–114} risendronate,¹¹⁵ and calcitonin,¹¹⁶ and the combinations generally resulted in greater BMD, although site-specificity may differ by agent. Alendronate combined with raloxifene was more effective at increasing BMD at the spine and hip than raloxifene alone and was more effective at the femoral neck than alendronate alone.¹¹⁷ Calcitonin given sequentially following PTH was not different than PTH alone¹¹⁸ and was not as effective at increasing BMD when compared to alendronate alone.¹¹⁹ BMD gains with PTH can be preserved when followed by alendronate¹²⁰ or estrogen therapy.¹²¹ However, recent data suggest that PTH given in combination with alendronate may not have synergistic effects.^{122,123}

Conclusions

Care of patients with diabetes should include an assessment of bone health. It has become increasingly clear that patients with type 1 diabetes have lower BMD and higher risk of fractures. Evidence is accumulating that patients with type 2 diabetes and complications, who were once thought to be protected from osteoporosis due to higher BMD and obesity, may in fact be at higher risk of fracture. Further work toward understanding the particular bone response to

diabetes is important for disease-specific tailored prevention and therapeutic strategies.

REFERENCES

- ¹NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy: Osteoporosis prevention, diagnosis and therapy. *JAMA* 285:785–795, 2001
- ²Looker A, Orwoll E, Johnston CC, Lindsay R, Wahner HW, Dunn W, Calvo M, Harris T, Heyse S: Prevalence of low femoral bone density in older U.S. adults from NHANES III. *J Bone Miner Res* 12:1761–1768, 1997
- ³Melton LJ, 3rd: Who has osteoporosis? A conflict between clinical and public health perspectives. *J Bone Miner Metab* 15:2309–2314, 2000
- ⁴Gullberg B, Johnell O, Kanis J: World-wide projections for hip fracture. *Osteoporos Int* 7:407–413, 1997
- ⁵Torgerson DJ, Dolan P: Prescribing by general practitioners after an osteoporotic fracture. *Ann Rheum Dis* 57:378–379, 1998
- ⁶Cuddihy M, Gabriel S, Crowson C, Atkinson EJ, Tabini C, O’Fallon WM, Melton, LJ 3rd: Osteoporosis intervention following distal forearm fractures: a missed opportunity? *Arch Intern Med* 162:421–426, 2002
- ⁷Cummings S, Black DM, Rubin S: Lifetime risks of hip, Colles’, or vertebral fracture and coronary heart disease among white postmenopausal women. *Arch Intern Med* 149:2445–2448, 1989
- ⁸Leibson C, Tosteson A, Gabriel S, Ransom J, Melton LJ: Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. *J Am Geriatr Soc* 50:1644–1650, 2002
- ⁹Cooper C, Atkinson EJ, Jacobsen S, O’Fallon WM, Melton LJ 3rd: Population based study of survival after osteoporosis fracture. *Am J Epidemiol* 137:1001–1005, 1993
- ¹⁰Riggs BL, Melton LJ, 3rd: The worldwide problem of osteoporosis: insights afforded by epidemiology. *Bone* 17:505S–511S, 1995
- ¹¹Kannus P, Parkkari J, Sievanen H, Heinonen A, Vuori I, Jarvinen M: Epidemiology of hip fractures. *Bone* 18:57S–63S, 1996
- ¹²Nevitt M, Ettinger B, Black D, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings S: The association of radiographically detected vertebral fractures with back pain and function: a prospective study. *Ann Intern Med* 128:793–800, 1998
- ¹³Meyer HE, Tverdal A, Falch JA: Risk factors for hip fracture in middle-aged Norwegian women and men. *Am J Epidemiol* 137:1203–1211, 1993
- ¹⁴Forsen L, Meyer HE, Midthjell K, Edna TH: Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey. *Diabetologia* 42:920–925, 1999
- ¹⁵Nicodemus KK, Folsom AR: Type 1 and type 2 diabetes and incident hip fractures in post-

menopausal women. *Diabetes Care* 24:1192–1197, 2001

¹⁶Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM: Menopausal estrogen therapy and hip fractures. *Ann Intern Med* 95:28–31, 1981

¹⁷Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR: Older women with diabetes have an increased risk of fracture: a prospective study. *J Clin Endocrinol Metab* 86:32–38, 2001

¹⁸van Daele PL, Stolk RP, Burger H, Algra D, Grobbee DE, Hofman A, Birkenhager JC, Pols HA: Bone density in non-insulin-dependent diabetes mellitus: the Rotterdam Study. *Ann Intern Med* 122:409–414, 1995

¹⁹Hirano Y, Kishimoto H, Hagino H, Teshima R: The change of bone mineral density in secondary osteoporosis and vertebral fracture incidence. *J Bone Miner Metab* 17:119–124, 1999

²⁰Heath HD, Melton LJD, Chu CP: Diabetes mellitus and risk of skeletal fracture. *N Engl J Med* 303:567–570, 1980

²¹Seeley DG, Kelsey J, Jergas M, Nevitt MC: Predictors of ankle and foot fractures in older women: the Study of Osteoporotic Fractures Research Group. *J Bone Miner Res* 11:1347–1355, 1996

²²Meyer HE, Tverdal A, Falch JA, Pedersen JI: Factors associated with mortality after hip fracture. *Osteoporos Int* 11:228–232, 2000

²³Marshall D, Johnell O, Wedel H: Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* 312:1254–1259, 1996

²⁴Miller PD, Siris ES, Barrett-Connor E, Faulkner K, Wehren L, Abbott T, Chen Y, Berger M, Santora A, Sherwood L: Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the national osteoporosis risk assessment. *J Bone Miner Res* 17:2222–2230, 2002

²⁵Rix M, Andreassen H, Eskildsen P: Impact of peripheral neuropathy on bone density in patients with type 1 diabetes. *Diabetes Care* 22:827–831, 1999

²⁶World Health Organization: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group. WHO Technical Report Series No. 843, Geneva, World Health Organization, 1994, p. 1–129

²⁷Levin ME, Boisseau VC, Avioli LV: Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. *N Engl J Med* 294:241–245, 1976

²⁸Selby PL: Osteopenia and diabetes. *Diabet Med* 5:423–428, 1988

²⁹Roe TF, Mora S, Costin G, Kaufman F, Carlson ME, Gilsanz V: Vertebral bone density in insulin-dependent diabetic children. *Metabolism* 40:967–971, 1991

³⁰Munoz-Torres M, Jodar E, Escobar-Jimenez F, Lopez-Ibarra PJ, Luna JD: Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. *Calcif Tissue Int* 58:316–319, 1996

- ³¹Tuominen JT, Impivaara O, Puukka P, Ronnema T: Bone mineral density in patients with type 1 and type 2 diabetes. *Diabetes Care* 22:1196–1200, 1999
- ³²Valerio G, del Puente A, Esposito-del Puente A, Buono P, Mozzillo E, Franzese A: The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. *Horm Res* 58:266–272, 2002
- ³³Liu EY, Wactawski-Wende J, Donahue RP, Dmochowski J, Hovey KM, Quattrin T: Does low bone mineral density start in post-teenage years in women with type 1 diabetes? *Diabetes Care* 26:2365–2369, 2003
- ³⁴Barrett-Connor E, Holbrook TL: Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. *JAMA* 268:3333–3337, 1992
- ³⁵Weinstock RS, Goland RS, Shane E, Clemens TL, Lindsay R, Bilezikian JP: Bone mineral density in women with type II diabetes mellitus. *J Bone Miner Res* 4:97–101, 1989
- ³⁶Kayath MJ, Dib SA, Vieiaa JG: Prevalence and magnitude of osteopenia associated with insulin-dependent diabetes mellitus. *J Diabetes Complications* 8:97–104, 1994
- ³⁷Mathiassen B, Nielsen S, Ditzel J, Rodbro P: Long-term bone loss in insulin-dependent diabetes mellitus. *J Intern Med* 227:325–327, 1990
- ³⁸Forst T, Pfutzner A, Kann P, Schehler B, Lobmann R, Schafer H, Andreas J, Bockisch A, Beyer J: Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. *Diabet Med* 12:874–879, 1995
- ³⁹Ivers RQ, Cumming RG, Mitchell P, Peduto AJ: Diabetes and risk of fracture: the Blue Mountains Eye Study. *Diabetes Care* 24:1198–1203, 2001
- ⁴⁰Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM: Bone loss and bone turnover in diabetes. *Diabetes* 44:775–782, 1995
- ⁴¹Campos Pastor MM, Lopez-Ibarra PJ, Escobar-Jimenez F, Serrano Pardo MD, Garcia-Cervigon AG: Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. *Osteoporos Int* 11:455–459, 2000
- ⁴²Raskin P, Stevenson MR, Barilla DE, Pak CY: The hypercalciuria of diabetes mellitus: its amelioration with insulin. *Clin Endocrinol (Oxf)* 9:329–335, 1978
- ⁴³Gertner JM, Tamborlane WV, Horst RL, Sherwin RS, Felig P, Genel M: Mineral metabolism in diabetes mellitus: changes accompanying treatment with a portable subcutaneous insulin infusion system. *J Clin Endocrinol Metab* 50:862–866, 1980
- ⁴⁴Thalassinos NC, Hadjiyanni P, Tzanela M, Alevizaki C, Philokiprou D: Calcium metabolism in diabetes mellitus: effect of improved blood glucose control. *Diabet Med* 10:341–344, 1993
- ⁴⁵Nagasaka S, Murakami T, Uchikawa T, Ishikawa SE, Saito T: Effect of glycemic control on calcium and phosphorus handling and parathyroid hormone level in patients with non-insulin-dependent diabetes mellitus. *Endocr J* 42:377–383, 1995
- ⁴⁶Okazaki R, Totsuka Y, Hamano K, Ajima M, Miura M, Hirota Y, Hata K, Fukumoto S, Matsumoto T: Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. *J Clin Endocrinol Metab* 82:2915–2920, 1997
- ⁴⁷Christensen JO, Svendsen OL: Bone mineral in pre- and postmenopausal women with insulin-dependent and non-insulin-dependent diabetes mellitus. *Osteoporos Int* 10:307–311, 1999
- ⁴⁸Barrett-Connor E, Kritiz-Silverstein D: Does hyperinsulinemia preserve bone? *Diabetes Care* 19:1388–1392, 1996
- ⁴⁹Stolk RP, Van Daele PL, Pols HA, Burger H, Hofman A, Birkenhager JC, Lamberts SW, Grobbee DE: Hyperinsulinemia and bone mineral density in an elderly population: the Rotterdam Study. *Bone* 18:545–549, 1996
- ⁵⁰Kwon DJ, Kim JH, Chung KW, Lee JW, Kim SP, Lee HY: Bone mineral density of the spine using dual energy X-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. *J Obstet Gynaecol Res* 22:157–162, 1996
- ⁵¹Haffner SM, Bauer RL: The association of obesity and glucose and insulin concentrations with bone density in premenopausal and postmenopausal women. *Metabolism* 42:735–738, 1993
- ⁵²Gunczler P, Lanes R, Paoli M, Martinis R, Villaroel O, Weisinger JR: Decreased bone mineral density and bone formation markers shortly after diagnosis of clinical type 1 diabetes mellitus. *J Pediatr Endocrinol Metab* 14:525–528, 2001
- ⁵³McCabe LR, Botolin S: Osmoadaptation impairs osteoblast differentiation (Abstract). *J Bone Miner Res* 18 (Suppl. 2):S229, 2003
- ⁵⁴Thraillkill KM, Liu L, Wahl EC, Liu Z, Bunn RC, Hogue W, Suva LJ, Perrien DS, Fowlkes JL, Aronson J, Lumpkin CK: New bone formation is impaired in a model of type I diabetes mellitus (Abstract). *J Bone Miner Res* 18 (Suppl. 2):S169, 2003
- ⁵⁵Jehle PM, Jehle DR, Mohan S, Bohm BO: Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type I and type 2 diabetes mellitus patients. *J Endocrinol* 159:297–306, 1998
- ⁵⁶Rosato MT, Schneider SH, Shapses SA: Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. *Calcif Tissue Int* 63:107–111, 1998
- ⁵⁷Bjorgaas M, Haug E, Johnsen HJ: The urinary excretion of deoxypyridinium cross-links is higher in diabetic than in nondiabetic adolescents. *Calcif Tissue Int* 65:121–124, 1999
- ⁵⁸Loder RT: The influence of diabetes mellitus on the healing of closed fractures. *Clin Orthopedics* 232:210–216, 1988
- ⁵⁹Krakauer JC, McKenna MJ, Rao DS, Whitehouse FW: Bone mineral density in diabetes. *Diabetes Care* 20:1339–1340, 1997
- ⁶⁰Agency for Healthcare Research and Quality: Evidence Report/Technology Assessment No. 28: Osteoporosis in postmenopausal women: diagnosis and monitoring. Rockville, Md., Agency for Healthcare research and Quality, 2001 (AHRQ Publication no. 01-E031)
- ⁶¹Albrand G, Munoz G, Sornay-Rendu E, DuBoeuf F, Delmas PD: Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. *Bone* 32:78–85, 2003
- ⁶²Klotzbuecher C, Ross PD, Landsman P, Abbott T, Berger M: Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. *J Bone Miner Res* 4:721–739, 2000
- ⁶³Lindsay R, Silverman S, Cooper C, Hanley DA, Barton I, Broy S, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E: Risk of new vertebral fracture in the year following a fracture. *JAMA* 285:320–23, 2001
- ⁶⁴Black D, Arden N, Palmero L, Pearson J, Cummings S: Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. *J Bone Miner Res* 14:821–28, 1999
- ⁶⁵Youm T, Koval K, Kummer F, Zuckerman J: Do all hip fractures result from a fall? *Am J Orthopedics* 28:190–194, 1999
- ⁶⁶Schwartz AV, Hillier TA, Sellmeyer DE, Resnick HE, Gregg E, Ensrud KE, Schreiner PJ, Margolis KL, Cauley JA, Nevitt MC, Black DM, Cummings SR: Older women with diabetes have a higher risk of falls: a prospective study. *Diabetes Care* 25:1749–1754, 2002
- ⁶⁷Cummings S, Melton LJ, 3rd: Epidemiology and outcomes of osteoporotic fractures. *Lancet* 359:1761–1766, 2002.
- ⁶⁸Looker A, Wahner HW, Dunn W, Calvo M, Harris T, Heyse S, Johnston CC, Lindsay RL: Proximal femur bone mineral levels of US adults. *Osteoporos Int* 5:389–409, 1995
- ⁶⁹Bhudsonok G, Wang M, Eckert K, Matkin C, Marcus R, Bachrach L: Differences in bone mineral in young Asian and Caucasian Americans may reflect differences in bone size. *J Bone Miner Res* 11:1545–1556, 1996
- ⁷⁰Finkelstein JS, Klubanski A, Neer RM: A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. *J Clin Endocrinol Metab* 81:1152–1155, 1996
- ⁷¹Kjaer K, Hagen C, Sando SH, Eshoj O: Epidemiology of menarche and menstrual disturbances in an unselected group of women with insulin-dependent diabetes mellitus compared to controls. *J Clin Endocrinol Metab* 75:524–529, 1992
- ⁷²Lunt H, Florkowski CM, Cundy T, Kendall D, Brown LJ, Elliot JR, Wells JE, Turner JG: A population-based study of bone mineral density in women with longstanding type 1 (insulin dependent) diabetes. *Diabetes Res Clin Pract* 40:31–38, 1998
- ⁷³Peveler RC, Fairburn CG, Boller I, Dunger D: Eating disorders in adolescents with IDDM: a controlled study. *Diabetes Care* 15:1356–1360, 1992
- ⁷⁴Ensrud KE, Lipschutz RC, Cauley JA, Seeley D, Nevitt MC, Scott J, Orwoll ES, Genant HK, Cummings SR: Body size and hip fracture risk in older women: a prospective study: Study of Osteoporotic Fractures Research Group. *Am J Med* 103:274–280, 1997
- ⁷⁵Nevitt MC: Epidemiology of osteoporosis. *Rheum Dis Clin North Am* 2:535–539, 1994

Downloaded from <http://diabetesjournals.org/clinical/article-pdf/22/1/10/498207/0010.pdf> by guest on 17 August 2022

- ⁷⁶Wallace C, Reiber GE, LeMaster J, Smith DG, Sullivan K, Hayes S, Vath C: Incidence of falls, risk factors for falls, and fall-related fractures in individuals with diabetes and a prior foot ulcer. *Diabetes Care* 25:1983–1986, 2002
- ⁷⁷Hanley DA, Brown JP, Tenenhouse A, Olszynski WP, Ioannidis G, Berger C, Prior JC, Pickard L, Murray TM, Anastassiades T, Kirkland S, Joyce C, Joseph L, Papaioannou A, Jackson SA, Poliquin S, Adachi JD: Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. *J Bone Miner Res* 18:784–790, 2003
- ⁷⁸Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H: HMG-CoA reductase inhibitors and the risk of fractures. *JAMA* 283:3205–3210, 2000
- ⁷⁹LaCroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CE, McNeeley G, Passaro MD, Jackson RD: Statin use, clinical fracture and bone density in postmenopausal women: results from the Women's Health Initiative observational study. *Ann Intern Med* 139:97–104, 2003
- ⁸⁰Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B: Bone is a target for the anti-diabetic compound rosiglitazone. *Endocrinology* 2003. Published online ahead of print. Epub Sept 18.
- ⁸¹Lecka-Czernik B, Suva LJ, Gaddy D, Rzonca SO: Glitazones, the anti-diabetic PPAR-gamma agonists, pose a significant risk of bone loss: differential effects of rosiglitazone and netoglitazone (Abstract). *J Bone Miner Res* 18 (Suppl. 2):S24, 2003
- ⁸²U.S. Preventive Services Task Force: Screening for osteoporosis in postmenopausal women: recommendations and rationale. *Ann Intern Med* 137:526–528, 2002
- ⁸³Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B: Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. *Osteoporos Int* 12:989–995, 2001
- ⁸⁴Institute of Medicine: *DRI: Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride*. Washington, D.C., National Academy Press, 1999
- ⁸⁵National Institutes of Health: Optimal calcium intake. *Conn Med* 58:613–623, 1994
- ⁸⁶Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N, Cranney A, Adachi J, Tugwell P, Josse R, Greenwood C, Guyatt G: Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analyses of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. *Endocr Rev* 23:560–569, 2002
- ⁸⁷Nelson ME, Fiatarone MA, Morganti CM, Trice I, Greenberg RA, Evans WJ: Effect of high-intensity strength training on multiple risk factors for osteoporotic fractures. *JAMA* 272:1909–1914, 1994
- ⁸⁸Gillespie L, Gillespie W, Robertson M, Lamb S, Cumming R, Rowe B: Interventions for preventing falls in elderly people (Cochrane Review). In *The Cochrane Library* Issue 4, 2003
- Chichester, UK, John Wiley and Sons
- ⁸⁹Kannus P, Parkkari J, Niemi S, Palvanen M, Jarvinen M, Vuori I: Prevention of hip fracture in ambulatory elderly. *N Engl J Med* 343:1506–1513, 2000
- ⁹⁰Jude EB, Selby PL, Lilliestone P, Mawer EB, Page SR, Donohoe M, Foster AVM, Edmonds ME, Boulton AJM: Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. *Diabetologia* 44:2032–2037, 2001
- ⁹¹Brown SA, Rosen CJ: Osteoporosis. *Med Clin North Am* 87:1039–1063, 2003
- ⁹²Delmas P: Treatment of postmenopausal osteoporosis. *Lancet* 359:2018–2026, 2002
- ⁹³Elder G: Pathophysiology and recent advances in the management of renal osteodystrophy. *J Bone Miner Res* 17:2094–2105, 2002
- ⁹⁴Writing Group for the PEPI: Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. *JAMA* 276:1389–1396, 1996
- ⁹⁵Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D, Cranney A: Meta-analyses of therapies for postmenopausal osteoporosis. V: Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. *Endocr Rev* 23:529–539, 2002
- ⁹⁶Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts N: Effects of estrogen plus progestin on risk of fracture and bone mineral density: the women's health initiative randomized trial. *JAMA* 290:1729–1738, 2003
- ⁹⁷de Groen P, Lubbe D, Hirsch L, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick M, Pinkas H, Wang K: Esophagitis associated with the use of alendronate. *N Engl J Med* 335:1016–1021, 1996
- ⁹⁸Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G: Meta-analyses of therapies for postmenopausal osteoporosis. II: Meta-analysis of alendronate for the treatment of postmenopausal osteoporosis. *Endocr Rev* 23:508–516, 2002
- ⁹⁹Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G: Meta-analyses of therapies for postmenopausal osteoporosis. III: Meta-analysis of risenedronate for the treatment of postmenopausal osteoporosis. *Endocr Rev* 23:517–523, 2002
- ¹⁰⁰Schnitzer T, Bone H, Crepaldi G, Adams S, McClung M, Kiel D, Felsenberg D, Recker R, Tonino R, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ: Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis: alendronate once-weekly study group. *Aging (Milano)* 12:1–12, 2000
- ¹⁰¹Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, Yates J, de Papp A, Palmisano J: Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. *Mayo Clin Proc* 77:1044–1052, 2002
- ¹⁰²Riggs BL, Hartmann L: Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. *N Engl J Med* 348:618–629, 2003
- ¹⁰³Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta J, Stakkestad J, Gluer CG, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. *JAMA* 282:637–645, 1999
- ¹⁰⁴Barrett-Connor E, Ensrud KE, Harper KD, Mason TM, Sashegyi A, Krueger KA, Andersen P: Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. *Clin Ther* 25:919–930, 2003
- ¹⁰⁵Ensrud KE, Cauley JA, Zhou L, Mason TM, Bowman PJ, Harper KD: Effect of raloxifene hydrochloride (RLX) on bone mineral density (BMD) and bone turnover markers in diabetic women: the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. *J Bone Miner Res* 16 (Suppl. 1):S415, 2001
- ¹⁰⁶Chestnut C, III, Silverman S, Andriano K, Genant H, Giomona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. *Am J Med* 109:267–276, 2000
- ¹⁰⁷Rosen CJ, Bilezikian JP: Clinical review 123: Hot topic: anabolic therapy for osteoporosis. *J Clin Endocrinol Metab* 86:957–964, 2001
- ¹⁰⁸Body J, Gaich G, Scheele W, Kulkarni P, Miller P, Peretz A, Dore R, Correa-Rotter R, Papaioannou A, Cumming D, Hodsman A: A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. *J Clin Endocrinol Metab* 87:4528–4535, 2002
- ¹⁰⁹Cosman F, Nieves J, Woelfert L, Shen V, Lindsay RT: Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. *J Bone Miner Res* 13:1051–1055, 1998
- ¹¹⁰Neer RM, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J, Hodsman A, Eriksen EF, Ish-Shalom S, Genant H, Wang O, Mitlak BH: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 344:1434–1441, 2001
- ¹¹¹Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB: Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. *Toxicol Pathol* 30:312–321, 2002
- ¹¹²Lindsay R, Cosman F, Lobo R, Walsh B, Harris S, Reagan J, Liss C, Melton M, Byrnes C:

Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. *J Clin Endocrinol Metab* 84:3076–3081, 1999

¹¹³Bone H, Greenspan S, McKeever C, Bell N, Davidson M, Downs R, Emkey R, Meunier P, Miller S, Mulloy A, Rocker RR, Weiss SR, Keyden N, Musliner T, Suryawanshi S, Yates J, Lombardi A: Alendronate and estrogen effects in postmenopausal women with low bone mineral density. *J Clin Endocrinol Metab* 85:720–726, 2000

¹¹⁴Palomba S, Orio F, Colao A, Di Carlo C, Sena T, Lombardi G, Zullo F, Mastrantonio P: Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. *J Clin Endocrinol Metab* 87:1502–1508, 2002

¹¹⁵Harris S, Eriksen EF, Davidson M, Ettinger M, Moffett A, Baylink D, Crusan C, Chines A: Effect of combined risendronate and hormone replacement therapies on bone mineral density in postmenopausal women. *J Clin Endocrinol Metab* 86:1890–1897, 2001

¹¹⁶Tiras M, Noyan V, Yildiz A, Biberoglu K: Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate. *Climacteric* 3:92–101, 2000

¹¹⁷Johnell O, Scheele W, Lu Y, Reginster J, Need A, Seeman E: Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal

women with osteoporosis. *J Clin Endocrinol Metab* 87:985–992, 2002

¹¹⁸Hodsman A, Fraher L, Watson P, Ostbye T, Stitt L, Adachi J, Taves D, Drost D: A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. *J Clin Endocrinol Metab* 82:620–628, 1997

¹¹⁹Downs R, Bell N, Ettinger M, Walsh B, Favus M, Mako B, Wang L, Smith M, Gormley G, Melton M: Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. *J Clin Endocrinol Metab* 85:1783–1788, 2000

¹²⁰Rittmaster R, Bolognese M, Ettinger M, Hanley DA, Hodsman A, Kendler D, Rosen C: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. *J Clin Endocrinol Metab* 85:2129–2134, 2000

¹²¹Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R: Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. *J Bone Miner Res* 16:925–931, 2001

¹²²Black D, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garner P, Bouxsein ML, Bilezikian JP, Rosen CJ: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. *N Engl J Med* 349:1207–1215, 2003

¹²³Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee HY, Neer RM: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. *N Engl J Med* 349:1216–1226, 2003

¹²⁴Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C: Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. *Endocr Rev* 23:570–578, 2002

¹²⁵McClung M, Geusens P, Miller P, Zippel H, Bensen W, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY: Effect of risendronate on the risk of hip fracture in elderly women. *N Engl J Med* 344:333–340, 2001

¹²⁶Black D, Cummings S, Karpf D, Cauley JA, Thompson D, Nevitt M, Bauer D, Genant, HK, Haskell W, Marcus R, Ott SM, Tomer JA, Quandt SA, Reiss TF, Ensrud KE: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. *Lancet* 348:1535–1541, 1996

Sue A. Brown, MD, and Julie L. Sharpless, MD, are assistant professors of medicine in the Division of Endocrinology at the University of North Carolina, Chapel Hill.